Net Cash Provided by (Used in) Operating Activities in USD of RELMADA THERAPEUTICS, INC. from Q4 2012 to Q1 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.
Summary
Relmada Therapeutics, Inc. quarterly/annual Net Cash Provided by (Used in) Operating Activities history and growth rate from Q4 2012 to Q1 2025.
  • Relmada Therapeutics, Inc. Net Cash Provided by (Used in) Operating Activities for the quarter ending March 31, 2025 was -$18.1M, a 38.6% decline year-over-year.
  • Relmada Therapeutics, Inc. annual Net Cash Provided by (Used in) Operating Activities for 2024 was -$51.8M, a 0.19% decline from 2023.
  • Relmada Therapeutics, Inc. annual Net Cash Provided by (Used in) Operating Activities for 2023 was -$51.7M, a 50.2% increase from 2022.
  • Relmada Therapeutics, Inc. annual Net Cash Provided by (Used in) Operating Activities for 2022 was -$104M, a 13% decline from 2021.
Net Cash Provided by (Used in) Operating Activities, Quarterly (USD)
Net Cash Provided by (Used in) Operating Activities, YoY Quarterly Growth (%)
Net Cash Provided by (Used in) Operating Activities, Annual (USD)
Net Cash Provided by (Used in) Operating Activities, YoY Annual Growth (%)

RELMADA THERAPEUTICS, INC. Quarterly Net Cash Provided by (Used in) Operating Activities (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2025 -$18.1M -$5.03M -38.6% Jan 1, 2025 Mar 31, 2025 10-Q 2025-05-12
Q1 2024 -$13M +$3.47M +21% Jan 1, 2024 Mar 31, 2024 10-Q 2025-05-12
Q1 2023 -$16.5M +$2.92M +15.1% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-08
Q1 2022 -$19.4M -$3.34M -20.8% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-11
Q1 2021 -$16.1M -$12.7M -370% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-05
Q1 2020 -$3.42M -$1.41M -70.2% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-12
Q3 2019 -$2.53M -$863K -51.7% Jul 1, 2019 Sep 30, 2019 10-Q 2019-11-13
Q1 2019 -$2.01M Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-15
Q3 2018 -$1.67M -$692K -70.7% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-13
Q3 2017 -$979K +$1.17M +54.3% Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-13
Q3 2016 -$2.14M +$1.07M +33.3% Jul 1, 2016 Sep 30, 2016 10-Q 2016-11-10
Q3 2015 -$3.22M -$894K -38.5% Jul 1, 2015 Sep 30, 2015 10-Q 2016-11-10
Q3 2014 -$2.32M -$1.91M -468% Jul 1, 2014 Sep 30, 2014 10-Q 2015-11-06
Q1 2014 -$1.02M -$617K -154% Jan 1, 2014 Mar 31, 2014 8-K 2014-05-27
Q4 2013 -$9.12K* -$10.6K Sep 1, 2013 Nov 30, 2013 10-Q 2014-01-13
Q3 2013 -$409K Jul 1, 2013 Sep 30, 2013 10-Q 2014-11-07
Q1 2013 -$400K Jan 1, 2013 Mar 31, 2013 8-K 2014-05-27
Q4 2012 $1.5K* Sep 1, 2012 Nov 30, 2012 10-Q 2014-01-13

RELMADA THERAPEUTICS, INC. Annual Net Cash Provided by (Used in) Operating Activities (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 -$51.8M -$96.6K -0.19% Jan 1, 2024 Dec 31, 2024 10-K 2025-03-27
2023 -$51.7M +$52.1M +50.2% Jan 1, 2023 Dec 31, 2023 10-K 2025-03-27
2022 -$104M -$11.9M -13% Jan 1, 2022 Dec 31, 2022 10-K 2024-03-19
2021 -$91.9M -$64.1M -230% Jan 1, 2021 Dec 31, 2021 10-K 2023-03-23
2020 -$27.8M -$15.7M -130% Jan 1, 2020 Dec 31, 2020 10-K 2022-03-25
2019 -$12.1M -$6.09M -101% Jan 1, 2019 Dec 31, 2019 10-K 2021-03-24
2018 -$6M +$464K +7.18% Jul 1, 2017 Jun 30, 2018 10-KT 2020-03-26
2017 -$6.47M +$6.68M +50.8% Jul 1, 2016 Jun 30, 2017 10-K 2018-09-28
2016 -$13.1M +$3.08M +19% Jul 1, 2015 Jun 30, 2016 10-K 2017-09-28
2015 -$16.2M Jul 1, 2014 Jun 30, 2015 10-K 2016-09-09
2013 -$2.24M -$654K -41.3% Jan 1, 2013 Dec 31, 2013 10-K 2015-09-11
2012 -$1.58M Jan 1, 2012 Dec 31, 2012 10-KT 2014-09-09
* An asterisk sign (*) next to the value indicates that the value is likely invalid.